Literature DB >> 1939653

Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion.

H H Watzke1, A Wallmark, N Hamaguchi, P Giardina, D W Stafford, K A High.   

Abstract

Factor X (FX) is a vitamin K-dependent plasma protein required for the intrinsic and extrinsic pathways of blood coagulation. FXSanto Domingo is a hereditary FX deficiency which is characterized clinically by a severe bleeding diathesis. The proposita has a FX activity of less than 1% and a FX antigen of less than 5%. We have determined the molecular basis of the defect in the FXSanto Domingo gene by amplification of all eight exons with polymerase chain reaction and subsequent sequence analysis. The patient is homozygous for a G----A transition in exon I at codon -20 (numbering the alanine at the NH2 terminus of the mature protein as +1), resulting in the substitution of arginine for glycine in the carboxy-terminal part of the signal peptide. This amino acid change occurs near the presumed cleavage site of the signal peptidase. We hypothesized that the mutation might prevent cleavage by the signal peptidase which in turn would impair proper secretion of the FX protein. To test this hypothesis, we compared the expression of wild type and mutant FX cDNA in a human kidney cell line. Wild type and mutant constructs in the expression vector pCMV4 were introduced into the human embryonic kidney cell line 293 by calcium phosphate transfection. FX antigen levels in the supernatant of the cells harboring the wild type construct were 2.4 micrograms/10(7) cells per 24 h, whereas antigen levels in media from cells containing the FXSanto Domingo construct were undetectable. No FX antigen was detected in the cell lysates of cells transfected with the mutant construct. To insure that the difference in protein levels was not due to a difference in steady state levels of mRNA, Northern analysis was performed on RNA from the cell lysates of both constructs. The results showed a transcript of the same size, present in roughly equal amounts, in both cases. Thus, the defect in the signal sequence of FXSanto Domingo exerts its effect posttranscriptionally. FXSanto Domingo is the first described example of a bleeding diathesis due to a mutation in the signal sequence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939653      PMCID: PMC295703          DOI: 10.1172/JCI115484

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Isolation and characterization of human blood-coagulation factor X cDNA.

Authors:  R K Kaul; B Hildebrand; S Roberts; P Jagadeeswaran
Journal:  Gene       Date:  1986       Impact factor: 3.688

2.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

3.  The gene for clotting factor 10 is mapped to 13q32----qter.

Authors:  N J Royle; M R Fung; R T MacGillivray; J L Hamerton
Journal:  Cytogenet Cell Genet       Date:  1986

4.  Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C.

Authors:  S P Leytus; D C Foster; K Kurachi; E W Davie
Journal:  Biochemistry       Date:  1986-09-09       Impact factor: 3.162

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

6.  The factor-X defect: recognition of abnormal forms of factor X.

Authors:  K W Denson; A Lurie; F De Cataldo; P M Mannucci
Journal:  Br J Haematol       Date:  1970-03       Impact factor: 6.998

7.  Characterization of an almost full-length cDNA coding for human blood coagulation factor X.

Authors:  M R Fung; C W Hay; R T MacGillivray
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Characterization of a cDNA coding for human factor X.

Authors:  S P Leytus; D W Chung; W Kisiel; K Kurachi; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

9.  Molecular defect in coagulation factor XFriuli results from a substitution of serine for proline at position 343.

Authors:  H L James; A Girolami; D S Fair
Journal:  Blood       Date:  1991-01-15       Impact factor: 22.113

10.  Vitamin K-dependent carboxylase. Control of enzyme activity by the "propeptide" region of factor X.

Authors:  J E Knobloch; J W Suttie
Journal:  J Biol Chem       Date:  1987-11-15       Impact factor: 5.157

View more
  4 in total

1.  Factor X M402T: a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency.

Authors:  Yushi Chikasawa; Keiko Shinozawa; Kagehiro Amano; Kyoichi Ogata; Takeshi Hagiwara; Takashi Suzuki; Hiroshi Inaba; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2014-07-27       Impact factor: 2.490

2.  Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.

Authors:  C E Jackson; R E Fischer; A P Hsu; S M Anderson; Y Choi; J Wang; J K Dale; T A Fleisher; L A Middelton; M C Sneller; M J Lenardo; S E Straus; J M Puck
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

3.  Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus.

Authors:  M Ito; Y Oiso; T Murase; K Kondo; H Saito; T Chinzei; M Racchi; M O Lively
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

4.  One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa.

Authors:  E Morishita; K Yamaguchi; H Asakura; M Saito; M Yamazaki; Y Ontachi; T Mizutani; M Kato; S Nakao
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.